QURE - uniQure NV Stock Price, Fair Value and News

$5.70-0.12 (-2.06%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

QURE Price Action

Last 7 days

-16.2%

Last 30 days

-13.6%

Last 90 days

-12.4%

Trailing 12 Months

-15.3%

QURE RSI Chart

QURE Valuation

Market Cap

277.8M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

9.72

EV/EBITDA

-0.4

Price/Free Cashflow

-1.5

QURE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

QURE Fundamentals

QURE Revenue

Revenue (TTM)

28.6M

Rev. Growth (Yr)

62.54%

Rev. Growth (Qtr)

-79.44%

QURE Earnings

Earnings (TTM)

-239.5M

Earnings Growth (Yr)

50.45%

Earnings Growth (Qtr)

21.17%

QURE Profitability

EBT Margin

-821.68%

Return on Equity

-429.05%

Return on Assets

-37.09%

Free Cashflow Yield

-66.51%

QURE Investor Care

Shares Dilution (1Y)

1.95%

Diluted EPS (TTM)

-4.95

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.0M	27.7M	28.6M	0
2023	108.3M	110.1M	111.9M	15.8M
2022	419.6M	315.2M	210.9M	106.5M
2021	159.1M	280.8M	402.4M	524.0M
2020	14.8M	22.4M	30.0M	37.5M
2019	8.9M	8.4M	6.3M	7.3M
2018	13.3M	11.4M	12.3M	11.3M
2017	24.1M	24.6M	19.7M	13.1M
2016	14.2M	17.8M	21.5M	25.1M
2015	0	0	0	10.6M
2014	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

CEO	Mr. Matthew Craig Kapusta
WEBSITE	uniqure.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	501

uniQure NV Frequently Asked Questions

What is the ticker symbol for uniQure NV? What does QURE stand for in stocks?

QURE is the stock ticker symbol of uniQure NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of uniQure NV (QURE)?

As of Wed Nov 20 2024, market cap of uniQure NV is 277.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QURE stock?

You can check QURE's fair value in chart for subscribers.

Is uniQure NV a good stock to buy?

The fair value guage provides a quick view whether QURE is over valued or under valued. Whether uniQure NV is cheap or expensive depends on the assumptions which impact uniQure NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QURE.

What is uniQure NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, QURE's PE ratio (Price to Earnings) is -1.16 and Price to Sales (PS) ratio is 9.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QURE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on uniQure NV's stock?

In the past 10 years, uniQure NV has provided -0.072 (multiply by 100 for percentage) rate of return.